Ze-Jun Zhou1, Ping Zhan1, Yong Song1. 1. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China.
Abstract
BACKGROUND: Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial. METHODS: To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival. RESULTS: A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies. CONCLUSIONS: PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.
BACKGROUND: Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial. METHODS: To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival. RESULTS: A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies. CONCLUSIONS:PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.
Authors: B Martin; M Paesmans; T Berghmans; F Branle; L Ghisdal; C Mascaux; A-P Meert; E Steels; F Vallot; J-M Verdebout; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640
Authors: B Martin; M Paesmans; C Mascaux; T Berghmans; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2004-12-13 Impact factor: 7.640
Authors: Julius Strauss; Christopher R Heery; Jeffrey Schlom; Ravi A Madan; Liang Cao; Zhigang Kang; Elizabeth Lamping; Jennifer L Marté; Renee N Donahue; Italia Grenga; Lisa Cordes; Olaf Christensen; Lisa Mahnke; Christoph Helwig; James L Gulley Journal: Clin Cancer Res Date: 2018-01-03 Impact factor: 12.531
Authors: Peter R Bucciarelli; Kay See Tan; Neel P Chudgar; Whitney Brandt; Joseph Montecalvo; Takashi Eguchi; Yuan Liu; Rania Aly; William D Travis; Prasad S Adusumilli; David R Jones Journal: J Thorac Oncol Date: 2017-10-31 Impact factor: 15.609
Authors: Rathi N Pillai; Madhusmita Behera; Taofeek K Owonikoko; Alice O Kamphorst; Suchita Pakkala; Chandra P Belani; Fadlo R Khuri; Rafi Ahmed; Suresh S Ramalingam Journal: Cancer Date: 2017-09-28 Impact factor: 6.860